Highlights

  • HC Wainwright & Co. revised its outlook from Neutral to Buy on June 4, 2025
  • Average price target stands at USD 41.82, up from the current price of USD 23.52
  • Institutional ownership rose 11.25% last quarter to 42.8 million shares

On June 4, 2025, HC Wainwright & Co. upgraded AnaptysBio (NasdaqGS:ANAB) from Neutral to Buy, signaling a shift in sentiment around the biotechnology company. The change follows updated analyst projections that suggest a significant upside potential based on the current share price.

As of June 2, 2025, the average one-year price target for AnaptysBio sits at USD 41.82 per share, which implies a 77.81% increase from its latest reported closing price of USD 23.52. Analyst estimates vary widely, ranging from a low of USD 18.18 to a high of USD 94.50, reflecting uncertainty around near-term execution and long-term valuation.

Despite the optimistic price forecast, AnaptysBio faces notable financial headwinds. Its projected annual revenue is USD 21 million, reflecting a sharp 80.85% year-over-year decline. In addition, the company is expected to post a non-GAAP earnings per share of -USD 4.36, highlighting continued losses.

Investor sentiment has grown more positive in recent months. There are currently 341 institutional holders of ANAB stock, up by 11 from the previous quarter, a 3.33% increase. The total number of shares held by institutions rose by 11.25%, reaching approximately 42.8 million. Additionally, the average portfolio weight of all funds investing in AnaptysBio increased by 75.23% to 0.18%, signaling a rise in institutional exposure.

While the revised analyst rating and increased institutional ownership may reflect improving confidence, AnaptysBio’s declining revenue and negative EPS forecast underscore ongoing operational challenges.